Novel Stool-Based CRC Screening Test Yields Impressive Early Results (GI & Endoscopy News)

A new multimodal stool nucleic acid (mm-sNA) test, ColoAlert by Mainz Biomed, has shown remarkable sensitivity and specificity in detecting colorectal cancer (CRC) and advanced precancerous lesions (APLs). Presented at DDW 2024, the study highlighted the test’s use of mRNA, DNA, and hemoglobin biomarkers combined with an AI/machine learning (AI/ML) algorithm, achieving 97% sensitivity and specificity for CRC and 82% sensitivity and 97% specificity for APLs.